Munich - Curetis, a molecular diagnostics company based in Holzgerlingen near Stuttgart, has extended its Series B financing round by EUR 14.5 million.
The Series B round was originally completed in April 2013. Its lead investor, HBM Partners, one of the world's leading investors in the healthcare/medical sector, has also joined in the extension funding on a pro rata basis, together with the other existing investors aeris Capital, BioMed Invest, CD Venture, Forbion Capital, LSP Life Sciences Partners, Roche Venture Fund, the management of Curetis and private angel investors, generating a total of EUR 7.5 million. Biotechnology company QIAGEN and the LSP Health Economics Fund are additionally providing a total of EUR 7 million as new investors. This round of financing increases the equity capital raised by Curetis AG to more than EUR 63.5 million. The funding is earmarked for further growth and to help prepare the company for future exit options such as strategic partnerships, M&A or an initial public offering (IPO).
A team from CMS Hasche Sigle led by lead partner Stefan-Ulrich Müller advised Curetis on all legal aspects of the extension. The firm also provided legal advice on the original Series B round of financing. It also advised LSP Life Sciences Partners during the Series A financing round for Curetis in 2009, as well as Curetis and the original investors on the extension of Series A in 2011.
Established in 2007, Curetis AG focuses on the development and commercialisation of products for the diagnosis of serious infectious diseases. QIAGEN N.V. is listed on the TecDAX in Germany. It generated sales of more than USD 1.3 billion in 2013. LSP Life Sciences Partners is a leading investment firm in the European healthcare sector with offices in Amsterdam, Munich and Boston. HBM Partners manages healthcare investments amounting to around USD 1 billion worldwide.
Stefan-Ulrich Müller, Lead Partner
Dr Tilman Weichert
Katrin Bauer, all Venture Capital
Stefan Lehr, Competition
Michaela Ott, Tax